Lupus

In the 4 decades since 1976, the incidence and prevalence of lupus nephritis has increased among the population in Minnesota, according to data published in Arthritis Rheumatology.

SAN DIEGO — Limited assessment tools make it difficult to determine the prevalence and severity of cognitive disorders in patients with rheumatic and autoimmune diseases, according to a speaker at the Congress of Clinical Rheumatology West.

After a third COVID-19 vaccine dose, patients with autoimmune rheumatic diseases often fail to mount an effective response useful in preventing omicron breakthrough infection, according to data published in Annals of the Rheumatic Diseases.

Litifilimab is superior to placebo in improving CLASI-A scores among patients with cutaneous lupus erythematosus over 16 weeks, according to data published in the New England Journal of Medicine.

MILAN — Deucravacitinib demonstrated efficacy and safety in treating patients with systemic lupus erythematosus and sustained improvement up to 48 weeks.

Litifilimab is superior to placebo in reducing tender and swollen joints among patients with systemic lupus erythematosus, according to phase 2 trial data published in the New England Journal of Medicine.

Patients with systemic lupus erythematous achieved an improved serological response following a booster COVID-19 vaccine dose, according to data collected during the omicron BA.1 wave in New York and published in The Lancet Rheumatology.

Belimumab treatment and standard therapy caused greater kidney outcomes among East Asian patients with lupus nephritis compared with standard therapy alone.

Sufficient disease control prior to conception can reduce the risk for pregnancy complications in patients with rheumatic conditions, according to a press release announcing data published in Rheumatic Disease Clinics of North America.

Ustekinumab failed to demonstrate superiority to placebo among patients with active systemic lupus erythematosus, according to phase-3 data published in Annals of the Rheumatic Diseases.